HK1075406A1 - Biologically stable liquid composition of fvIII, of vwf or of fviii/vwf complex of human origin - Google Patents

Biologically stable liquid composition of fvIII, of vwf or of fviii/vwf complex of human origin

Info

Publication number
HK1075406A1
HK1075406A1 HK05109078A HK05109078A HK1075406A1 HK 1075406 A1 HK1075406 A1 HK 1075406A1 HK 05109078 A HK05109078 A HK 05109078A HK 05109078 A HK05109078 A HK 05109078A HK 1075406 A1 HK1075406 A1 HK 1075406A1
Authority
HK
Hong Kong
Prior art keywords
fviii
vwf
liquid composition
human origin
stable liquid
Prior art date
Application number
HK05109078A
Other languages
English (en)
Inventor
Salvador Grancha Gamon
Juna Ignacio Jorquera Nieto
Pere Ristol Debart
Marta Massot Riera
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of HK1075406A1 publication Critical patent/HK1075406A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
HK05109078A 2003-10-03 2005-10-13 Biologically stable liquid composition of fvIII, of vwf or of fviii/vwf complex of human origin HK1075406A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302298A ES2229931B1 (es) 2003-10-03 2003-10-03 Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.

Publications (1)

Publication Number Publication Date
HK1075406A1 true HK1075406A1 (en) 2005-12-16

Family

ID=34307115

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05109078A HK1075406A1 (en) 2003-10-03 2005-10-13 Biologically stable liquid composition of fvIII, of vwf or of fviii/vwf complex of human origin

Country Status (13)

Country Link
US (1) US20050074866A1 (es)
EP (1) EP1522312B1 (es)
JP (1) JP4388875B2 (es)
AR (1) AR047756A1 (es)
AT (1) ATE357245T1 (es)
CA (1) CA2481593C (es)
DE (1) DE602004005392T2 (es)
ES (2) ES2229931B1 (es)
HK (1) HK1075406A1 (es)
MX (1) MXPA04009246A (es)
PL (1) PL1522312T3 (es)
PT (1) PT1522312E (es)
UY (1) UY28531A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660531A2 (en) * 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN101952016A (zh) 2007-12-28 2011-01-19 巴克斯特国际公司 重组vwf配方
TWI670072B (zh) 2008-10-21 2019-09-01 美商巴克斯歐塔公司 凍乾的重組ｖｗｆ調配物
WO2010049488A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
AU2012318303B2 (en) 2011-10-18 2015-09-03 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
DK3066119T3 (en) * 2013-11-08 2018-11-12 Csl Ltd NEW PROCEDURE FOR CONCENTRATION OF THE VON WILLEBRAND FACTOR OR COMPLEXES OF IT
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP4322918A1 (en) 2021-04-13 2024-02-21 Grifols Worldwide Operations Limited Liquid composition comprising factor viii or factor viii/von willebrand factor complex
AU2022326188A1 (en) * 2021-08-11 2024-02-22 Grifols Worldwide Operations Limited Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359463A (en) * 1980-11-26 1982-11-16 Rock Gail A Stabilization of Factor VIII activity in whole blood or blood plasma
JPS59116228A (ja) * 1982-12-24 1984-07-05 Green Cross Corp:The 血液凝固第８因子脂肪小体製剤の製法
AT379510B (de) * 1983-05-20 1986-01-27 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
CA2378751C (en) * 1999-07-13 2012-11-06 Biovitrum Ab Stable factor viii compositions

Also Published As

Publication number Publication date
UY28531A1 (es) 2005-03-31
MXPA04009246A (es) 2005-04-06
ES2280924T3 (es) 2007-09-16
DE602004005392D1 (de) 2007-05-03
ES2229931A1 (es) 2005-04-16
EP1522312A1 (en) 2005-04-13
AR047756A1 (es) 2006-02-22
PL1522312T3 (pl) 2007-08-31
CA2481593A1 (en) 2005-04-03
JP2005112855A (ja) 2005-04-28
ATE357245T1 (de) 2007-04-15
PT1522312E (pt) 2007-06-19
CA2481593C (en) 2009-10-20
JP4388875B2 (ja) 2009-12-24
US20050074866A1 (en) 2005-04-07
EP1522312B1 (en) 2007-03-21
DE602004005392T2 (de) 2007-12-06
ES2229931B1 (es) 2006-01-16

Similar Documents

Publication Publication Date Title
HK1075406A1 (en) Biologically stable liquid composition of fvIII, of vwf or of fviii/vwf complex of human origin
GB2414990B (en) Biologically active native biomatrix composition
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
IL174637A0 (en) Fibrosis-inducing agents, compositions containing the same and medical implants containing the same
IL174636A0 (en) Compositions containing anti-scarring agents and medical implants incorporating the same
IL173299A (en) 2,4-Pyrimidindiamine derivatives, preparations containing them and their use
IL181689A0 (en) Aptamers to von willebrand factor and pharmaceutical compositions containing the same
EP1552814A4 (en) FRAGRANCE COMPOSITION
EG24078A (en) Liquid pharmaceutical composition
GB0208696D0 (en) Fabric treatment composition
HK1183446A1 (en) Stable pharmaceutical composition containing factor viii viii
GB0321911D0 (en) Improvements in or relating to medical devices
GB0229806D0 (en) Fabric care composition
IL183044A0 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
GB0225292D0 (en) Fabric care composition
TWI341211B (en) Liquid skin cleansing composition
EP1789065A4 (en) BIOLOGICALLY ACTIVE COMPOSITION
EP1605794A4 (en) ARTIFICIAL, LIQUID NAIL
GB2416123B (en) Stable carprofen composition
GB0205347D0 (en) Biologically active complex
GB0219281D0 (en) Fabric care composition
EP1600445A4 (en) CURATIVE PREPARATION
HK1081451A1 (en) Medicinal composition
HK1062274A1 (en) Medicinal composition
AU2003249396A8 (en) Novel cyclic peptides and use thereof as anti-microbial agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210924